伏立康唑原研药与仿制药的有效性、安全性及经济性评价 点击下载
| 论文标题： | 伏立康唑原研药与仿制药的有效性、安全性及经济性评价 |
| 英文标题： | |
| 中文摘要： | 目的 评价伏立康唑仿制药与原研药的有效性、安全性和经济性。方法收集本院使用集采中选伏立康唑仿制药（仿制药组）或非中选原研药（原研药组）治疗真菌感染的患者信息。采用倾向性得分匹配消除偏倚。通过临床疗效、影像学表现和微生物试验评估综合疗效，根据感染真菌菌种、基础疾病等对不同人群进行分层并评估不同分层的疗效；使用药物不良反应发生情况评价安全性；采用总费用和药品的用药频度、日均费用等评估经济性。结果有436例患者被纳入，经匹配后，两组各有190例。在有效性方面，伏立康唑仿制药和原研药的有效率分别为62.63%和59.47%（P＝0.528）。在安全性方面，伏立康唑仿制药和原研药的不良反应发生率分别为13.68%和7.89%（P＝0.069）。在经济性方面，伏立康唑仿制药平均总费用4636.26元，原研药平均总费用8613.20元（P＜0.001）；仿制药在集采实施后药品替换率上升至87.30%，日均费用下降59.08%。结论伏立康唑仿制药在治疗真菌感染的有效性和安全性与原研药相似，且在治疗成本方面经济性更佳。 |
| 英文摘要： | OBJECTIVE To evaluate the efficacy， safety and cost-effectiveness of generic drugs and original drugs of voriconazole. METHODS The information of patients who used voriconazole generic drugs selected in National Centralized Drug Procurement （generic drug group） or non-selected original drugs （original drug group） in the treatment of fungal infection was collected from the our hospital. The propensity score matching was carried out to eliminate bias. The comprehensive efficacy was evaluated according to clinical efficacy， image findings and microbiological test， and stratified analysis of different populations was conducted based on fungal species， underlying diseases， etc.， the efficacy of different stratifications was evaluated. Evaluation of safety was performed by using the incidence of adverse reactions. The total cost， defined daily doses （DDDs） and defined daily dose cost （DDDc） were used to evaluate the cost-effectiveness. RESULTS A total of 436 patients were included， and there were 190 patients in each group after matching. In terms of efficacy， the effective rates of voriconazole generic drugs and original drugs were 62.63% and 59.47% （P＝0.528）； in terms of safety， the incidence of adverse reactions caused by generic drugs and original drugs of voriconazole was 13.68% and 7.89%， respectively（P＝0.069）. In terms of cost-effectiveness， the average total cost of generic drugs was 4 636.26 yuan， and that of original drugs was 8 613.20 yuan （P＜0.001）. After the implementation of National Centralized Drug Procurement， replacement rate of generic drugs increased to 87.30%， and DDDc decreased by 59.08%. CONCLUSIONS The efficacy and safety of voriconazole generic drugs are similar to those of original drugs in the treatment of fungal infection， and it is more cost-effective in terms of treatment cost. |
| 期刊： | 2024年第35卷第07期 |
| 作者： | 唐甘翎；谢祥威；罗鲜丹；陆艳丽；蒋慧娴；李静怡；黄肖曼；张宏亮 |
| 英文作者： | TANG Ganling， XIE Xiangwei，LUO Xiandan，LU Yanli，JIANG Huixian，LI Jingyi，HUANG Xiaoman，ZHANG Hongliang |
| 关键字： | 伏立康唑；国家药品集中采购；倾向性得分匹配；真实世界 |
| KEYWORDS： | voriconazole； National Centralized Drug Procurement； propensity score matching； real-world |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！